Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 7Salivary Gland Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Fulvestrant 65Letrozole 55Paclitaxel 54pembrolizumab 42Trastuzumab 42ribociclib 39Specimen Handling 36palbociclib 35Capecitabine 35Carboplatin 34Anastrozole 34Tamoxifen 32exemestane 31abemaciclib 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 26trastuzumab deruxtecan 24Radiotherapy 22Surveys and Questionnaires 20Blood Specimen Collection 20olaparib 18Biopsy 18Standard of Care 17Docetaxel 17Taxes 15130-nm albumin-bound paclitaxel 15eribulin 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Glutamate Carboxypeptidase II × 90 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡